Newsletter Tool

To view this email as a web page, click here

Today's Rundown

Eli Lilly follows up MiNA pact with a 2nd $1B-plus RNA collab, this time with ProQR
No joy for Ajovy: Teva's migraine drug can't find a win in meta-analysis versus Biohaven, AbbVie meds
Judge rules 'neigh' on using ivermectin for COVID-19, reversing earlier court decision
GSK, Pfizer and Johnson & Johnson race toward $10B+ RSV vaccine market: analyst
Amyloidosis biotech Attralus scores $116M for handful of treatments, imaging agent
Healthcare bankruptcies at all-time low, new report finds
As Congress considers drug price reforms, Merck, Lilly and Takeda execs warn of dire consequences
Smiths shuns previous medtech deal, instead opting for $2.4B from ICU Medical
Clover Health to integrate Assistant tool into athenahealth electronic medical record
COVID-19 tracker: Europe lists Guillain-Barré syndrome as rare AZ side effect; Novavax trials combined flu, coronavirus shot
Experts say adding dental coverage to Medicare won't trigger major shift away from Medicare Advantage
Glympse Bio names first medical chief, offering a peek at the clinical future of its disease-spotting biosensors

Featured Story

Eli Lilly follows up MiNA pact with a 2nd $1B-plus RNA collab, this time with ProQR

By Ben Adams

Eli Lilly is doubling down on RNA research as it pens another major biobucks pact with a small but promising biotech in the gene-silencing space.

No joy for Ajovy: Teva's migraine drug can't find a win in meta-analysis versus Biohaven, AbbVie meds

By Noah Higgins-Dunn

A new analysis from Teva pitting its long-acting migraine injectable Ajovy against oral rivals from Biohaven Pharmaceuticals and AbbVie doesn’t appear to separate its med from the up-and-comers as hoped.

Judge rules 'neigh' on using ivermectin for COVID-19, reversing earlier court decision

By Dave Muoio

An Ohio judge said hospitals should not be forced to administer ivermectin, a drug best known as a horse dewormer, for COVID-19 patients as there is no conclusive medical or scientific evidence supporting its use for the virus. The patient in question, however, still received the treatment for 13 days due to an earlier temporary decision.

GSK, Pfizer and Johnson & Johnson race toward $10B+ RSV vaccine market: analyst

By Eric Sagonowsky

While COVID-19 vaccines set all sorts of industry launch records, another potential megablockbuster vaccine market looms on the horizon. Some of pharma's top players, including Pfizer, Johnson & Johnson and GlaxoSmithKline are expected to be involved, one prominent industry analyst writes.

Amyloidosis biotech Attralus scores $116M for handful of treatments, imaging agent

By Emmy Lucas

Attralus Therapeutics has scored $116 million to bring a handful of amyloidosis therapies into the clinic along with an accompanying radiotracer diagnostic imaging agent.

Healthcare bankruptcies at all-time low, new report finds

By Anastassia Gliadkovskaya

The second quarter of this year was the lowest the Health Care Services Distress Research Index had ever recorded, according to a new report.

As Congress considers drug price reforms, Merck, Lilly and Takeda execs warn of dire consequences

By Kevin Dunleavy

As Congress considers sweeping legislation that would allow the government to negotiate prices for prescription drugs, industry execs are warning of dire consequences. For their part, employer and public interest groups are pushing for change that they view as now-or-never.

Smiths shuns previous medtech deal, instead opting for $2.4B from ICU Medical

By Conor Hale

After unveiling plans last month to sell its medical device business for $2 billion, the U.K. technology group announced that a better deal has come along from a once-previous suitor.

Clover Health to integrate Assistant tool into athenahealth electronic medical record

By Paige Minemyer

Clover Health is integrating its Clover Assistant into athenahealth electronic health records, the startup insurer announced Wednesday.

COVID-19 tracker: Europe lists Guillain-Barré syndrome as rare AZ side effect; Novavax trials combined flu, coronavirus shot

By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner

Europe's drug regulator listed Guillain-Barré syndrome as a potential rare side effect for AstraZeneca's pandemic vaccine. Pfizer picked a low vaccine dose on purpose, its chief scientist said. Plus more headlines.

Experts say adding dental coverage to Medicare won't trigger major shift away from Medicare Advantage

By Robert King

Experts say adding dental coverage to traditional Medicare likely won't lead to a massive shift away from Medicare Advantage, but industry concerns about payment structures persist.

Glympse Bio names first medical chief, offering a peek at the clinical future of its disease-spotting biosensors

By Andrea Park

Helping Glympse along its path through clinical trials, FDA approval and beyond will be Tram Tran, M.D., who joins the Cambridge, Mass.-based company as its first-ever chief medical officer.

PM Tracker